Preview

Атеротромбоз

Расширенный поиск

ИЗМЕНИЛИСЬ ЛИ НАШИ ПРЕДСТАВЛЕНИЯ О НЕОБХОДИМОСТИ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ С ПОЯВЛЕНИЕМ БОЛЕЕ МОЩНЫХ АНТИАГРЕГАНТОВ?

https://doi.org/10.21518/2307-1109-2017-2-32-42

Полный текст:

Аннотация

Несмотря на снижение смертности от ССЗ в последние десятилетия, связанное с широким применением гипотензивных, гипохолестеринемических и антитромбоцитарных препаратов, различные проявления ИБС сохраняют за собой одну треть в структуре смертности у лиц старше 35 лет [1—3]. В регионах с развитой системой здравоохранения сердечно-сосудистая смертность постепенно снижается, тем не менее смерть от различных проявлений ИБС остается ведущей в структуре смерти взрослого населения вне зависимости от уровня дохода [4].

Об авторе

Е. П. ПАНЧЕНКО
Институт кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» МЗ РФ
Россия
д.м.н., профессор


Список литературы

1. Rosamond W et al. Heart Disease and Stroke Statistics—2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, 117: e25–e146.

2. Nichols M, Townsend N, Scarborough P & Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J, 2014, 35: 2950–9.

3. Benjamin EJ et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 2017, 135: e146–e603.

4. Lopez AD, Mathers CD, Ezzati M, Jamison DT & Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (London, England), 2006, 367: 1747–57.

5. Панченко Е.П. Результаты трёхлетнего наблюдения за амбулаторными больными с клиническими проявлениями атеротромбоза (анализ российской популяции регистра REACH). Кардиология, 2009, 10: 9-14.

6. Steg PG, Bhatt DL, Wilson PWF et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA, 2007, 297: 1197–1206.

7. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet, 1996, 348: 1329-39.

8. Yusuf S et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl. J. Med., 2001, 345: 494–502.

9. Sh.Mehta,S.Yusuf, R.Peters et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358: 527-33.

10. Sabatine M et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with Elevation. N Engl J Med, 2005, March 9 352.

11. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet, 2005: 1607-21.

12. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acure coronary syndromes. N Engl J Med, 2009, 361(11): 1045-1057.

13. Wiviot SD, Braunwald E, McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357: 2001-15.

14. Mega J, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012, 366: 9-11.

15. Mauri L, Kereiakes D, Yeh R et al. Twelve or 12 months of dual antiplatelet therapyafter drug-eluting stents. N Engl J Med, 2014, 371: 2155-2166.

16. Bonaca M, Bhatt D, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med, 2015, 372: 1791–800.

17. Bhatt DL et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N. Engl. J. Med., 2006, 354: 1706–1717.

18. Stone GW, Maehara A, Lansky AJ et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med, 2011, 364: 226-235.

19. Udell JA, Bonaca M, Collet J-Ph et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: acollaborative meta-analysis of randomized trials. Eur Heart Journal, doi:10.1093/eurheartj/ehv443.

20. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. doi:10.1093/eurheartj/ehx393.

21. 2017 ESC fosed update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. doi:10.1093/eurheartj/ehx419.

22. Bergmeijer Th, Janssen P, Oevelen M et al. Inciedence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience. Cardiology, 2017, 138: 164-167.

23. Biscaglia S, Campo G, Pavasini R et al. Occurrence, causes and outcome after switching from ticagrelor to clopidogrel in real-life scenario: data from a prospective registry. Platelets, 2016. Doi:10.3109/09537104.2015.1119815.

24. Zettler M, Peterson E, McCoy L et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among mocardial infarction patients: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATEACS) obsevational study. Am Heart J, 2017, 183: 62-8.

25. Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart Journal, 2017. doi:10.1093/eurheartj/ehx175.

26. International Expert Consensus on Switching Platelet P2Y12 Receptor — Inhibiting Therapies. Circulation, 2017, 136: 00–00. DOI: 10.1161/CIRCULATIONAHA.117.031164.


Для цитирования:


ПАНЧЕНКО Е.П. ИЗМЕНИЛИСЬ ЛИ НАШИ ПРЕДСТАВЛЕНИЯ О НЕОБХОДИМОСТИ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ С ПОЯВЛЕНИЕМ БОЛЕЕ МОЩНЫХ АНТИАГРЕГАНТОВ? Атеротромбоз. 2017;(2):32-42. https://doi.org/10.21518/2307-1109-2017-2-32-42

For citation:


PANCHENKO E.P. HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS? Atherothrombosis Journal. 2017;(2):32-42. (In Russ.) https://doi.org/10.21518/2307-1109-2017-2-32-42

Просмотров: 176


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)